版本:
中国

BRIEF-AzurRx provides update on MS1819 phase II trial

April 11 AzurRx Biopharma Inc

* AzurRx provides update on MS1819 phase II trial

* AzurRx Biopharma Inc - Early results indicate that MS1819 exhibits a favorable safety profile Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐